目的 探討宮炎平膠囊聯(lián)合氟羅沙星治療慢性盆腔炎的臨床療效。方法 選取2014年7月—2017年7月在鄭州市第十五人民醫(yī)院進(jìn)行治療的慢性盆腔炎患者180例，根據(jù)入院號(hào)分為對(duì)照組（90例）和治療組（90例）。對(duì)照組口服氟羅沙星片，0.4 g/次，1次/d；治療組在對(duì)照組的基礎(chǔ)上口服宮炎平膠囊，0.75 g/次，3次/d。兩組患者均經(jīng)過(guò)4周治療。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀改善時(shí)間、血清學(xué)指標(biāo)及盆腔炎性包塊直徑和盆腔積液量。結(jié)果 治療后，對(duì)照組和治療組臨床總有效率分別為83.33%和96.67%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，治療組患者臨床癥狀改善時(shí)間均顯著短于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組血清白細(xì)胞介素-1β（IL-1β）、腫瘤壞死因子-α（TNF-α）、單核細(xì)胞趨化蛋白-1（MCP-1）、血紅素氧和酶-1（HO-1）水平均顯著降低（P < 0.05）；且治療組患者這些血清學(xué)指標(biāo)水平明顯低于對(duì)照組（P < 0.05）。治療后，兩組患者盆腔炎性包塊直徑明顯縮小，盆腔積液量明顯減少，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）；且治療組上述指標(biāo)改善后水平明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。結(jié)論 宮炎平膠囊聯(lián)合氟羅沙星治療慢性盆腔炎可有效降低機(jī)體炎癥反應(yīng)，促進(jìn)臨床癥狀改善，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical curative effect of Gongyanping Capsules combined with fleroxacin in treatment of chronic pelvic inflammatory. Methods Patients (180 cases) with chronic pelvic inflammatory in Zhengzhou Fifteenth People's Hospital from July 2014 to July 2017 were divided into control (90 cases) and treatment (90 cases) groups based on admission number. Patients in the control group were po administered with Fleroxacin Tablets, 0.4 g/time, once daily. Patients in the treatment group were po administered with Gongyanping Capsules on the basis of the control group, 0.75 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the time of clinical symptom improvement, serum cytokine levels, pelvic inflammatory mass diameter, and pelvic effusion volume in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 83.33% and 96.67%, respectively, and there were differences between two groups (P < 0.05). After treatment, the time of clinical symptom improvement in the treatment group was significantly shorter than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the IL-1β, TNF-α, MCP-1 and HO-1 levels in two groups were significantly decreased (P < 0.05), and the serum cytokine levels in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the pelvic inflammatory mass diameter in two groups was significantly reduced, pelvic effusion volume was significantly decreased, and the difference was statistically significant in the same group (P < 0.05), and these indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Gongyanping Capsules combined with fleroxacin in treatment of chronic pelvic inflammatory can effectively reduce inflammation and improve the clinical symptoms, which has a certain clinical application value.